What are typical EBITDA multiples for DME companies in 2026?

Standalone DME businesses with sub-$1M EBITDA typically clear 3.5x–5.5x. Regional DME platforms with $1M–$3M EBITDA clear 5x–7.5x. Multi-state DME platforms with $3M+ EBITDA clear 7x–10x. Specialized sub-segments (CPAP/respiratory recurring revenue, complex rehab, urological/ostomy, diabetes supplies) command premium multiples for recurring revenue and clinical complexity.

Who buys DME companies?

The most active DME buyers are large strategic platforms (AdaptHealth, Lincare, Apria/Owens & Minor, Rotech Healthcare, Aeroflow, Byram Healthcare), specialty DME consolidators (Numotion in complex rehab, ConvaTec in ostomy/urological), PE-backed DME platforms in active build mode, and mass distributors like Cardinal Health entering DME-adjacent segments.

What is driving DME M&A in 2026?

Three forces: (1) competitive bidding cycle dynamics that reward scale and efficient operations; (2) PE platforms in scale-up mode building national footprints; (3) demographic tailwinds driving demand growth across respiratory, complex rehab, and chronic-condition supplies. The mid-market remains fragmented despite a decade of consolidation.

How does Medicare competitive bidding affect DME valuation?

Medicare DMEPOS competitive bidding has reshaped DME economics over the past decade — favoring scaled, efficient operators and pressuring smaller independents. Buyers underwrite DME businesses with explicit attention to competitive bid contract status, reimbursement rate trends, and the relationship between Medicare-priced products and commercial / Medicare Advantage / managed Medicaid economics.

What due diligence is unique to DME M&A?

DME diligence focuses on accreditation status (ACHC, BOC, JCAHO), Medicare DMEPOS supplier standards compliance, state pharmacy and DME licensure, payer contract review (Medicare, MA, Medicaid managed care, commercial), competitive bid contract status, drug billing compliance for inhalation and infusion therapies, recall and lot management, and HIPAA compliance. CPAP, respiratory, and complex rehab each have sub-segment-specific diligence layers.

DME Company M&A 2026: Valuations & Buyers

Durable medical equipment (DME) M&A activity has accelerated meaningfully through 2025 and into 2026. After a decade of post-competitive-bidding consolidation, the DME mid-market remains surprisingly fragmented — and PE platforms, strategic consolidators, and specialty DME acquirers are all actively pursuing add-on acquisitions.

For owners of DME businesses across respiratory, complex rehab, urological/ostomy, diabetes supplies, and adjacent segments, 2026 represents a structurally favorable exit window. This guide covers what sellers should know.

Why DME M&A Is Active in 2026

1. Scale advantages from competitive bidding. A decade of Medicare DMEPOS competitive bidding has favored scaled, efficient operators. Smaller independents face structural margin pressure. Strategic consolidation is the operational answer.

2. PE platform scale-up. Multiple PE-backed DME platforms are in active build mode across respiratory, complex rehab, and specialty DME — generating consistent buyer demand for tuck-in acquisitions.

3. Demographic tailwinds. The 65+ population is growing, driving demand for respiratory equipment (CPAP, oxygen), mobility equipment, ostomy and urological supplies, and chronic-condition products.

4. Payer evolution. Medicare Advantage growth, managed Medicaid expansion, and MLTSS programs reshape DME payer mix. Sophisticated operators with diversified payer contracts trade at premium multiples.

5. Sub-sector specialization. Specialty DME segments (complex rehab, ostomy, urological, diabetes) command premium multiples for clinical complexity and recurring revenue characteristics.

Sub-Sector Valuation Ranges (Q2 2026)

Asset Type	EBITDA Size	Typical Multiple Range
General DME (single-state)	sub-$1M	3.5x–5.5x
General DME (regional)	$1M–$3M	5x–7.5x
General DME (multi-state)	$3M+	7x–10x
Respiratory / CPAP focused	$1M+	6x–9x
Respiratory / CPAP platform (multi-state)	$5M+	9x–12x
Complex rehab (CRT)	$1M+	7x–10x
Complex rehab platform	$5M+	10x–13x
Urological / ostomy supplies	$1M+	6x–9x
Diabetes supplies	$1M+	5.5x–8x
Hospital bed / mobility (rental-heavy)	$1M+	5x–8x
Specialty pediatric DME	$1M+	7x–10x

Premiums apply for: recurring revenue mix (resupply programs in CPAP, ostomy), accreditation breadth, multi-state licensure, diversified payer mix, and clean compliance histories.

Sub-Sector Considerations

Respiratory and CPAP

Recurring resupply revenue is a primary value driver
CPAP resupply programs generate predictable, durable revenue
Oxygen rental economics are reimbursement-sensitive
Adherence monitoring and clinical follow-up matter for buyer underwriting

Complex Rehab Technology (CRT)

Highly specialized — power wheelchairs, custom seating, complex mobility
Higher per-unit revenue, longer fulfillment cycles
Clinician (ATP, RTS) staffing is critical and scarce
Premium multiples reflect clinical complexity and limited buyer competition

Urological and Ostomy Supplies

Recurring resupply revenue model
Highly clinical patient base
Premium multiples for direct patient relationships and adherence programs

Diabetes Supplies

Includes CGM, insulin pumps, test strips
Distribution model varies (mail order vs. retail)
Manufacturer relationships matter

Hospital Beds, Lifts, and Mobility

Often rental-heavy model
Asset-intensive
Lower multiples reflect capex requirements

Pediatric DME

Specialized product mix
Often Medicaid waiver funded
Limited buyer pool but premium for quality programs

Payer Dynamics

Medicare Fee-for-Service

Competitive bid pricing for many product categories
Documentation requirements are intensive
DMERC / MAC oversight

Medicare Advantage

Plan-by-plan contract economics
Increasingly important share of senior population
Authorization and prior auth intensity

Medicaid Managed Care

State-by-state plan contracting
MLTSS integration where applicable
Rate variability

Commercial Insurance

Direct and PBM contracts
Higher-margin segment
Documentation-light vs. Medicare

Retail and Cash Pay

Direct-to-consumer
Highest margin
Scaling depends on marketing efficiency

The Most Active DME Buyers in 2026

Strategic Acquirers

AdaptHealth (NASDAQ: AHCO) — Major multi-segment DME platform
Lincare (Linde subsidiary) — Respiratory and oxygen focused
Apria / Owens & Minor (NYSE: OMI) — Multi-segment DME
Rotech Healthcare — Respiratory and oxygen
Aeroflow Health — Multi-segment, particularly maternity / breast pump focused
Byram Healthcare — Urological, ostomy, diabetes
Numotion — Complex rehab leader
ConvaTec — Ostomy and urological
Edgepark Medical Supplies (Cardinal Health subsidiary) — Multi-segment
Hims & Hers, Ro, others in DTC adjacent — Selective in DME-adjacent
Specialty regional DME consolidators

PE-Backed Platforms

Multiple PE platforms backing CPAP/respiratory consolidators
Complex rehab PE platforms
Specialty DME PE platforms
Independent sponsors and family offices

The DME buyer pool is concentrated among 15–30 firms across strategic and PE categories. Specialized advisor curation is essential for matching seller profile to right buyer.

Diligence Items Unique to DME M&A

Accreditation

ACHC, BOC, or Joint Commission accreditation status
Survey history
Re-accreditation timing

Medicare DMEPOS Compliance

Supplier Standards compliance
Surety bond
Documentation review (CMN, prescription requirements)
ZPIC, RAC, UPIC audit history
Recoupment exposure

Competitive Bid Contracts

Current contract status by competitive bidding area
Contract performance metrics
Renewal positioning

State Licensure

DME licensure across all states served
Pharmacy licensure (where applicable for inhalation drugs)
DEA registration (where applicable)

Inventory and Asset Management

Inventory valuation methodology
Rental fleet asset valuation and depreciation
Recall management documentation
Lot tracking

Payer Contracts

Medicare and MA contract review
Commercial contract review
Medicaid managed care contract review
Authorization-to-billing conversion

Workforce

Clinician licensure (RT, ATP, RTS)
Customer service and resupply staffing
Wage and hour compliance

Real Estate and Operations

Warehouse and distribution facilities
Lease assignability
Logistics infrastructure

Common DME Seller Mistakes

1. Underestimating Medicare audit exposure. Historical audit findings affect buyer underwriting. Document remediation thoroughly.

2. Disorganized payer contract documentation. Multi-payer, multi-product DME businesses require consolidated contract management.

3. Inventory valuation surprises. Inventory methodology should be agreed at LOI.

4. Underweighting recurring revenue documentation. For CPAP resupply, ostomy, urological — recurring revenue mechanics are the central value driver.

5. Single-buyer outreach. The DME buyer pool is concentrated but deep. Single-buyer conversations consistently leave value on the table.

6. Ignoring rental vs. capped rental economics. Rental product accounting and revenue recognition affect EBITDA quality. QoE work is essential.

Preparing a DME Platform for Sale

The 12–24 months before sale are when DME platforms most successfully build value.

Operationally:

Strengthen recurring revenue programs (CPAP resupply, ostomy resupply)
Diversify payer mix
Address audit findings and remediation
Document accreditation timing
Strengthen MA plan contracts
Reduce clinician turnover

Financially:

Sell-side Quality of Earnings — particularly important for rental product accounting
Inventory valuation analysis
Payer mix and rate analysis
Working capital benchmarking

Legally:

DME compliance audit
Supplier Standards review
Payer contract change-of-control review
Real estate assignment analysis

How Hendon Partners Helps DME Sellers

Hendon Partners advises owners of DME platforms across respiratory, complex rehab, urological / ostomy, diabetes, and pediatric DME segments through preparation, sale process, and close. Our buyer network includes the strategic acquirers and PE platforms most active in DME M&A in 2026.

Schedule a confidential DME-focused conversation with Hendon Partners →

Hendon Partners is a sell-side only M&A advisory firm with DME and home medical equipment transaction experience across the United States.

DME Company M&A in 2026: Valuations, Buyers, and What's Driving Deal Activity